ATORVASTATIN\EZETIMIBE: 1,236 Adverse Event Reports & Safety Profile
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
1,236
Total FAERS Reports
50 (4.0%)
Deaths Reported
540
Hospitalizations
1,236
As Primary/Secondary Suspect
76
Life-Threatening
63
Disabilities
Active Ingredient: ATORVASTATIN CALCIUM\EZETIMIBE ·
First Report: 20000101 · Latest Report: 20250815
What Are the Most Common ATORVASTATIN\EZETIMIBE Side Effects?
#1 Most Reported
Myalgia
130 reports (10.5%)
#2 Most Reported
Acute kidney injury
60 reports (4.9%)
#3 Most Reported
Pain
45 reports (3.6%)
All ATORVASTATIN\EZETIMIBE Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Myalgia | 130 | 10.5% | 0 | 13 |
| Acute kidney injury | 60 | 4.9% | 0 | 47 |
| Pain | 45 | 3.6% | 0 | 24 |
| Pain in extremity | 43 | 3.5% | 0 | 17 |
| Dizziness | 42 | 3.4% | 0 | 16 |
| Malaise | 42 | 3.4% | 3 | 25 |
| Pyrexia | 41 | 3.3% | 0 | 35 |
| Rhabdomyolysis | 40 | 3.2% | 1 | 30 |
| Arthralgia | 39 | 3.2% | 0 | 17 |
| Headache | 39 | 3.2% | 0 | 18 |
| Hepatic cytolysis | 39 | 3.2% | 0 | 24 |
| Dyspnoea | 36 | 2.9% | 0 | 22 |
| Muscle spasms | 36 | 2.9% | 0 | 6 |
| Interstitial lung disease | 35 | 2.8% | 2 | 24 |
| Nausea | 35 | 2.8% | 0 | 19 |
| Blood creatine phosphokinase increased | 34 | 2.8% | 0 | 4 |
| Cough | 34 | 2.8% | 0 | 24 |
| Rash | 34 | 2.8% | 0 | 24 |
| Drug-induced liver injury | 32 | 2.6% | 0 | 17 |
| Hepatocellular injury | 31 | 2.5% | 0 | 21 |
Who Reports ATORVASTATIN\EZETIMIBE Side Effects? Age & Gender Data
Gender: 39.0% female, 61.0% male. Average age: 65.6 years. Most reports from: FR. View detailed demographics →
Is ATORVASTATIN\EZETIMIBE Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2000 | 1 | 0 | 0 |
| 2003 | 5 | 0 | 0 |
| 2007 | 1 | 0 | 0 |
| 2010 | 1 | 0 | 0 |
| 2011 | 1 | 0 | 0 |
| 2012 | 1 | 0 | 1 |
| 2013 | 17 | 0 | 13 |
| 2014 | 8 | 1 | 1 |
| 2015 | 29 | 0 | 5 |
| 2016 | 90 | 4 | 33 |
| 2017 | 87 | 1 | 36 |
| 2018 | 146 | 6 | 78 |
| 2019 | 72 | 0 | 27 |
| 2020 | 79 | 0 | 24 |
| 2021 | 109 | 8 | 74 |
| 2022 | 78 | 3 | 49 |
| 2023 | 139 | 23 | 53 |
| 2024 | 105 | 0 | 65 |
| 2025 | 43 | 0 | 34 |
What Is ATORVASTATIN\EZETIMIBE Used For?
| Indication | Reports |
|---|---|
| Dyslipidaemia | 239 |
| Hypercholesterolaemia | 202 |
| Product used for unknown indication | 152 |
| Hyperlipidaemia | 62 |
| Coronary artery disease | 46 |
| Type iia hyperlipidaemia | 40 |
| Prophylaxis | 36 |
| Myocardial infarction | 29 |
| Myocardial ischaemia | 27 |
| Cardiovascular event prophylaxis | 23 |
ATORVASTATIN\EZETIMIBE vs Alternatives: Which Is Safer?
ATORVASTATIN\EZETIMIBE vs ATOSIBAN
ATORVASTATIN\EZETIMIBE vs ATOVAQUONE
ATORVASTATIN\EZETIMIBE vs ATOVAQUONE\PROGUANIL
ATORVASTATIN\EZETIMIBE vs ATRACURIUM
ATORVASTATIN\EZETIMIBE vs ATRIPLA
ATORVASTATIN\EZETIMIBE vs ATROPINE
ATORVASTATIN\EZETIMIBE vs ATROPINE\ATROPINE
ATORVASTATIN\EZETIMIBE vs ATROPINE\DIPHENOXYLATE
ATORVASTATIN\EZETIMIBE vs AUBAGIO
ATORVASTATIN\EZETIMIBE vs AUGMENTIN
Official FDA Label for ATORVASTATIN\EZETIMIBE
Official prescribing information from the FDA-approved drug label.